Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Your research
Country: Spain,Italy,France,Switzerland,Poland,Germany,Sweden,Russian Federation,United Kingdom,Turkey
nct
Update Il y a 5 ans
Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer
This randomized, open-label, crossover study will evaluate participants' preference and healthcare professional (HCP) satisfaction with SC versus IV Herceptin administration in HER2-positive early breast cancer. Participants will be randomized to receive either SC Herceptin or IV Herceptin every 3 weeks for Cycles 1 to 4, followed by crossover to the other treatment administration for Cycles 5 to 8. For up to 10 additional cycles (for a total of 18 cycles), participants will receive IV or SC Herceptin every 3 weeks.
Country
Canada
,
Denmark
,
France
,
Germany
,
Italy
,
Poland
,
Russian Federation
,
Spain
,
Sweden
,
Switzerland
,
Turkey
,
United Kingdom
,
organs
None
Specialty
None
Closed trial
More information
1